Umbilical cord vs bone marrow vs fat stem cells: three sources, compared

Mesenchymal stem cells (MSCs) exist in many tissues, but only three are practical sources for therapy: umbilical cord, bone marrow, and fat. The three sources are not interchangeable. Cord cells come from donated, screened tissue and are expanded into a characterized batch, while bone marrow and fat cells in U.S. same-day protocols are your own, at your age, with no significant expansion.

Celva's physician team at Hospital Angeles, Tijuana uses umbilical-cord (Wharton's jelly) MSCs most often, and donor bone-marrow MSCs for orthopedic and structural cases.

See the three side by side

Umbilical cord Allogeneic, donor-derived Bone marrow Autologous, your own Fat (adipose) Autologous, your own

Cord, bone marrow, or fat: how do the three sources compare?

If you're comparing umbilical cord stem cells vs bone marrow stem cells, or stem cells from fat, start with this table. Each source has a different yield, a different cell age, a different harvest procedure, and a different track record in the clinical literature. Many clinics make a choice without telling the patient one was made.

	Umbilical cord	Bone marrow	Fat (adipose)
Whose cells	A donor's Allogeneic, donor-derived	Your own Autologous	Your own Autologous
Cell age	Newborn	Your age	Your age
Typical yield	100M+ MSCs per batch, expanded	Low MSCs are well under 0.01% of the cells in a pull	Mixed cells (SVF), same-day
Harvest on you	None	Hip needle	Liposuction
Proliferative capacity	High	Age-limited	Age-limited
Standardized	Yes, by batch	No Each patient is their own batch	No Each patient is their own batch
Rejection	Rare immune response MSCs are immune-evasive, not invisible	No rejection risk By definition	No rejection risk By definition
In the U.S.	Needs an IND And cGMP infrastructure	Legal same-day Under the same-surgical-procedure exemption	Same-day, but a drug SVF is not exempt, say the FDA and two appeals courts

Cord-derived batches are produced by expansion; bone marrow and fat are typically delivered same-day without significant expansion. The dots are relative.

The marketing copy at most clinics flattens these distinctions into "stem cell therapy." The biology doesn't flatten them. It ranks them: cord first, fat last.

What are umbilical cord (Wharton's jelly) stem cells?

Donated, screened, expanded, then characterized and frozen.

The umbilical cord is the connective-tissue link between mother and newborn during pregnancy. After delivery, it's medical waste. With consent from the mother, the cord tissue can be donated, screened, and used as a source of mesenchymal stem cells. The cells come from Wharton's jelly, the gel-like connective tissue inside the cord.

Cord-derived MSCs are not embryonic. They're not from the baby. They're from the post-birth tissue that connected the placenta to the newborn, tissue that the body has finished using. The tissue is donated with consent and would otherwise be discarded.

Why the source matters biologically

Cord MSCs are functionally newborn cells. They've existed for nine months. They have not been exposed to decades of environmental stress, accumulated mutations, or age-related decline in expansion capacity. In laboratory expansion, they double more times before senescence than marrow-derived cells from a 60-year-old donor, meaning a single donor batch can yield well over a hundred million cells, characterized and frozen, ready for clinical use.

This is the basis of standardization: every patient receives cells from the same batch, with the same characterization, the same release testing, and the same potency. Autologous sources cannot offer this.

Donor screening

Cord donation requires extensive mother and infant screening. Tested in serious programs:

HIV
hepatitis B and C
syphilis
HTLV
CMV
West Nile
Zika
Chagas

and others depending on geography. The donor's medical history is reviewed. The infant's health at delivery is reviewed. The cord tissue itself is tested.

What are bone marrow stem cells, and what limits them?

Bone marrow aspirate has the longest history in regenerative medicine. The procedure: a large-bore needle into the posterior iliac crest of the patient's hip, suctioning out marrow under local anesthesia. The aspirate contains a mix of cells, including a small fraction of mesenchymal stem cells.

This is your own tissue, processed and returned to you. It can't be rejected, and there's no donor to match.

The yield problem

Bone marrow aspirate is rich in cells overall but sparse in MSCs specifically. Of the nucleated cells in a standard pull, well under 0.01% are mesenchymal stem cells. Without significant in-lab expansion, the MSC dose from a single bone marrow harvest is a small fraction of what a typical cord-derived dose contains.

Clinics that offer bone-marrow-derived therapy without expansion are giving a substantially lower MSC dose than clinics that use expanded cord cells. Whether that lower dose is clinically meaningful for a given condition is a real question, but it's not the same therapy.

The age problem

Bone marrow MSCs from a 70-year-old donor (yourself, at 70) are 70-year-old cells. They have accumulated 70 years of mutation, environmental stress, and replicative aging. They expand poorly in culture. They produce fewer growth factors and signaling molecules. They senesce sooner.

The cells are as old as the donor. Donor age at time of harvest

NewbornCord donor. High capacity
40Mid-career patient. Reduced capacity
60Typical patient age. Low capacity
75Older patient. Minimal capacity

For older patients, bone marrow as a source has structural disadvantages that no clinic can fix.

Read more: the harvest procedureShow less

The harvest procedure

Bone marrow harvest is invasive. It is done under local anesthesia, sometimes with sedation. Soreness at the puncture site is normal. Bruising is normal. Recovery from the harvest itself is typically a few days. Compared to receiving donor cells via IV, where the patient experiences nothing on harvest because nothing is being harvested from them, bone marrow involves real procedural burden.

For many U.S. clinics, this entire harvest happens the same day as treatment: morning harvest, afternoon injection, no real lab time in between. The result is a minimally manipulated autologous product (legally important under FDA same-surgical-procedure exemption) but a much smaller and less characterized dose than what a full manufacturing pipeline produces.

Stem cells from fat vs bone marrow: what is different?

Adipose-derived stem cells (ADSCs) come from a mini-liposuction harvest. A clinician aspirates a small volume of subcutaneous fat (typically 50 to 200 mL) under local anesthesia, processes the lipoaspirate to isolate the stromal vascular fraction, and uses the resulting cells directly or, where the rules allow it, expands them in culture.

Adipose tissue contains substantially more MSCs per gram than bone marrow. A typical fat harvest yields more cells than a typical bone marrow pull. Yield isn't rank. Same-day fat is delivered as a mixed stromal vascular fraction, not as characterized MSCs, which is why fat ranks last of the three sources.

The same caveats

Fat-derived MSCs are still your cells. They are still your age. They still have accumulated whatever environmental stress and replicative aging your tissues have accumulated. The age disadvantage compared to cord MSCs is the same.

And the harvest is still a procedure. Liposuction has real recovery: soreness, swelling, bruising at the harvest sites. For a patient already managing a chronic condition, adding a same-day surgical harvest to the treatment plan is a meaningful additional burden.

Stromal vascular fraction: mixed cells, not pure MSCs.

The FDA same-day pathway

In the U.S., the most common form of adipose stem cell therapy is "stromal vascular fraction" (SVF), a fat extract administered the same day. Many clinics say it falls under the FDA exception for autologous tissue transferred during the same surgical procedure. The FDA disagrees: it treats SVF as more than minimally manipulated, which makes it a drug, and two federal appeals courts agreed (2021 and 2024). Even where the claim is made, the same-day format constrains the therapy: no significant expansion, no batch testing, no characterized dose, no consistent product across patients.

Which source goes where, and why?

United States Autologous, same-day, minimally manipulated.

Sources: Bone marrow (fat-derived SVF is treated as a drug)
Pathway: The same-surgical-procedure exception
Expansion: Not permitted
Batch QC: None required
Dose: Whatever harvest yields

International cGMP Allogeneic, manufactured, characterized.

Sources: Umbilical cord
Pathway: cGMP / COFEPRIS
Expansion: High capacity
Batch QC: Full release panel
Dose: Defined per protocol

Most serious international cGMP programs use cord-derived allogeneic cells for the biological reasons. Most U.S. clinics that operate without manufacturing infrastructure use autologous cells for the regulatory reasons. The choice of source reflects the operating model.

Cord-derived cells require cGMP manufacturing infrastructure, and an international setting in most cases (U.S. regulatory constraints).

Which cells does Celva use, and how does the physician team choose?

Celva's physician team at Hospital Angeles, Tijuana does not use a single cell product across all patients. Source, biology, and mechanism expression are matched to the indication, delivery route, and clinical goal. Three allogeneic cell types are in routine use, each one carrying a different profile.

All three are manufactured in the cGMP lab at Hospital Angeles, using proprietary culture media, expansion methods, and protocols developed and used nowhere else. Most clinics don't manufacture at all; whether in Tijuana or Cancún, they buy frozen vials from a third-party lab. Every batch of ours is released against six tests: sterility, identity, viability, potency, endotoxin, mycoplasma. The lab work is the same; the cell type that ends up in the dose is the clinical decision.

The cell lab at Hospital Angeles, Tijuana

Umbilical-cord MSCs (UC-MSCs)

The preferred choice for systemic, neurologic, and autoimmune indications.

Read more: umbilical-cord MSCsShow less

Donated umbilical-cord tissue following full-term healthy births. Cells with high proliferative capacity and a robust secretome, higher anti-inflammatory cytokine expression, stronger immunomodulatory activity, greater paracrine output per cell than adult-derived cells. The preferred choice for systemic, neurologic, and autoimmune indications where broad immune and inflammatory recalibration is the primary goal. All six primary mechanisms are active. More on the six mechanisms.
Bone marrow MSCs, adult allogeneic (BM-MSCs)

Preferred for orthopedic and structural environments.

Read more: bone marrow MSCsShow less

Adult allogeneic donors. Bone marrow aspirate, expanded under cGMP conditions, screened and characterized to the same identity standards as UC-MSCs. BM-MSCs are more lineage-committed than UC-MSCs, biased toward musculoskeletal tissue types. Their cytokine profile includes higher expression of factors associated with tissue remodeling and extracellular matrix support. Preferred for orthopedic and structural environments where particularly strong anti-fibrotic and pro-angiogenic activity is needed to interrupt the fibrotic cascade in chronically inflamed joints and restore vascular supply.
Chondrocytes

Added alongside the MSCs in almost every joint case.

Read more: chondrocytesShow less

Mature cartilage cells from a screened donor, with no harvest procedure for you. Grown in the lab, they shift into a more active, chondroblast-like state (the young, dividing form of a cartilage cell). Added alongside the MSCs in almost every joint case.

How the call gets made

Cell selection is a clinical decision made during physician-team review, not a product the patient picks at intake.

Read more: the factors that drive itShow less

The factors that drive it: the target tissue and its biological environment, which of the six mechanisms needs to be most strongly expressed for the indication, the delivery route (IV for systemic mechanism expression; injection for localized), whether structural support is indicated alongside signaling (the chondrocyte question), and the condition's severity and evidence base. In many cases, a combination protocol (UC-MSCs systemically plus BM-MSCs and chondrocytes at the target site) produces a more complete response than any single cell type alone.

This is also why the program operates internationally. The full manufacturing pipeline (allogeneic expansion, batch characterization, indication-specific selection) requires regulatory and laboratory infrastructure that is not currently available under the U.S. same-day autologous pathway. More on the FDA line.

If a clinic won't name the source, what should you ask?

A clinic that flattens "stem cells" into one word without naming a source has decided not to tell you. The choice of source determines the dose, the consistency, and most of what the therapy can do.

"What's your donor screening protocol?"
"What pathogens are tested for?"
"Where are the donors located, and is the donation consented and IRB-overseen?"

A clinic operating a real cord-derived program can answer immediately. A clinic that purchases from outside labs may not know. A clinic claiming to use cord-derived MSCs without being able to describe its donor screening process is a clinic that doesn't control its supply chain.